Taro Pharmaceutical Industries Ltd has a consensus price target of $43, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on January 18, 2024, January 25, 2023, and August 15, 2022. With an average price target of $44 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 4.04% upside for Taro Pharmaceutical Industries Ltd from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
01/18/2024 | TARO | Buy Now | Taro Pharmaceutical Indus | $42.29 | 1.68% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $43 | Downgrade | Buy → Neutral | Get Alert |
01/25/2023 | TARO | Buy Now | Taro Pharmaceutical Indus | $42.29 | -17.24% | HC Wainwright & Co. | Raghuram Selvaraju | $54 → $35 | Maintains | Buy | Get Alert |
08/15/2022 | TARO | Buy Now | Taro Pharmaceutical Indus | $42.29 | 27.69% | HC Wainwright & Co. | Raghuram Selvaraju | $73 → $54 | Maintains | Buy | Get Alert |
01/31/2022 | TARO | Buy Now | Taro Pharmaceutical Indus | $42.29 | 72.62% | HC Wainwright & Co. | Raghuram Selvaraju | $75 → $73 | Maintains | Buy | Get Alert |
01/18/2022 | TARO | Buy Now | Taro Pharmaceutical Indus | $42.29 | 77.35% | HC Wainwright & Co. | Raghuram Selvaraju | $82 → $75 | Maintains | Buy | Get Alert |
07/28/2021 | TARO | Buy Now | Taro Pharmaceutical Indus | $42.29 | 93.9% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
06/02/2021 | TARO | Buy Now | Taro Pharmaceutical Indus | $42.29 | 89.17% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
The latest price target for Taro Pharmaceutical Indus (NYSE: TARO) was reported by HC Wainwright & Co. on January 18, 2024. The analyst firm set a price target for $43.00 expecting TARO to rise to within 12 months (a possible 1.68% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Taro Pharmaceutical Indus (NYSE: TARO) was provided by HC Wainwright & Co., and Taro Pharmaceutical Indus downgraded their neutral rating.
There is no last upgrade for Taro Pharmaceutical Indus.
The last downgrade for Taro Pharmaceutical Industries Ltd happened on January 18, 2024 when HC Wainwright & Co. changed their price target from $43 to $43 for Taro Pharmaceutical Industries Ltd.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Taro Pharmaceutical Indus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Taro Pharmaceutical Indus was filed on January 18, 2024 so you should expect the next rating to be made available sometime around January 18, 2025.
While ratings are subjective and will change, the latest Taro Pharmaceutical Indus (TARO) rating was a downgraded with a price target of $43.00 to $43.00. The current price Taro Pharmaceutical Indus (TARO) is trading at is $42.29, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.